Kwality Pharmaceuticals Limited (BOM:539997)
India
· Delayed Price · Currency is INR 933.60
-16.60 (-1.75%)
At close: May 27, 2025
Kwality Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Operating Revenue | 3,702 | 3,072 | 2,510 | 4,562 | 2,620 | Upgrade
|
| Other Revenue | - | - | - | - | 10.42 | Upgrade
|
| Revenue | 3,702 | 3,072 | 2,510 | 4,562 | 2,631 | Upgrade
|
| Revenue Growth (YoY) | 20.52% | 22.36% | -44.97% | 73.42% | 84.59% | Upgrade
|
| Cost of Revenue | 1,825 | 1,580 | 1,136 | 2,051 | 1,716 | Upgrade
|
| Gross Profit | 1,877 | 1,492 | 1,375 | 2,511 | 914.74 | Upgrade
|
| Selling, General & Admin | 437.84 | 326.29 | 301.26 | 202.76 | 160.1 | Upgrade
|
| Other Operating Expenses | 616.19 | 485.2 | 456.86 | 573.94 | 452.81 | Upgrade
|
| Operating Expenses | 1,237 | 1,007 | 907.71 | 883.61 | 677.85 | Upgrade
|
| Operating Income | 640.18 | 484.53 | 466.8 | 1,627 | 236.9 | Upgrade
|
| Interest Expense | -98.78 | -103.87 | -60.2 | -29.17 | -26.75 | Upgrade
|
| Interest & Investment Income | - | 1.3 | 1.23 | 1.23 | 1.81 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 12.66 | 16.62 | 0.96 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | - | -0 | -0 | - | Upgrade
|
| EBT Excluding Unusual Items | 541.4 | 381.96 | 420.48 | 1,616 | 212.91 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.02 | 0.54 | - | -0.2 | Upgrade
|
| Asset Writedown | - | - | -70.51 | - | - | Upgrade
|
| Other Unusual Items | - | -70.99 | -94.78 | - | - | Upgrade
|
| Pretax Income | 541.4 | 310.99 | 255.72 | 1,616 | 212.72 | Upgrade
|
| Income Tax Expense | 143.37 | 74.83 | 62.93 | 416.28 | 63.84 | Upgrade
|
| Earnings From Continuing Operations | 398.03 | 236.16 | 192.8 | 1,199 | 148.88 | Upgrade
|
| Minority Interest in Earnings | 0.42 | 1.8 | 0.93 | 0.53 | 2.58 | Upgrade
|
| Net Income | 398.45 | 237.96 | 193.72 | 1,200 | 151.46 | Upgrade
|
| Net Income to Common | 398.45 | 237.96 | 193.72 | 1,200 | 151.46 | Upgrade
|
| Net Income Growth | 67.44% | 22.84% | -83.86% | 692.24% | 82.11% | Upgrade
|
| Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Change (YoY) | 0.11% | - | - | 0.00% | - | Upgrade
|
| EPS (Basic) | 38.36 | 22.93 | 18.67 | 115.64 | 14.60 | Upgrade
|
| EPS (Diluted) | 38.36 | 22.93 | 18.67 | 115.64 | 14.60 | Upgrade
|
| EPS Growth | 67.27% | 22.84% | -83.86% | 692.22% | 82.11% | Upgrade
|
| Free Cash Flow | 294.25 | 131.42 | -62.92 | 54.45 | 33.06 | Upgrade
|
| Free Cash Flow Per Share | 28.33 | 12.66 | -6.06 | 5.25 | 3.19 | Upgrade
|
| Gross Margin | 50.71% | 48.56% | 54.75% | 55.04% | 34.77% | Upgrade
|
| Operating Margin | 17.29% | 15.77% | 18.59% | 35.66% | 9.01% | Upgrade
|
| Profit Margin | 10.76% | 7.75% | 7.72% | 26.30% | 5.76% | Upgrade
|
| Free Cash Flow Margin | 7.95% | 4.28% | -2.51% | 1.19% | 1.26% | Upgrade
|
| EBITDA | 823.08 | 680.12 | 616.38 | 1,734 | 301.83 | Upgrade
|
| EBITDA Margin | 22.23% | 22.14% | 24.55% | 38.01% | 11.47% | Upgrade
|
| D&A For EBITDA | 182.9 | 195.59 | 149.58 | 106.91 | 64.93 | Upgrade
|
| EBIT | 640.18 | 484.53 | 466.8 | 1,627 | 236.9 | Upgrade
|
| EBIT Margin | 17.29% | 15.77% | 18.59% | 35.66% | 9.01% | Upgrade
|
| Effective Tax Rate | 26.48% | 24.06% | 24.61% | 25.77% | 30.01% | Upgrade
|
| Revenue as Reported | 3,721 | 3,090 | 2,540 | 4,597 | 2,636 | Upgrade
|
| Advertising Expenses | - | 0.66 | 1.67 | 1.25 | 0.73 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.